Williams Cancer Institute

Towards Targeted Triumph: SYNC-T™ Shows Promise in Treating Advanced Prostate Cancer

SYNC-T™, an innovative in situ personalized therapy developed by SYNCROMUNE® Inc., has shown promising results in the treatment of metastatic castrate-resistant prostate cancer (mCRPC), as announced at the American Association for Cancer Research (AACR) Annual Meeting 2024. The Phase 1 trial revealed an impressive overall response rate (ORR) of 85%.

Dr. James Armitage, Chairman of Syncromune’s Scientific Advisory Board, hailed SYNC-T as a groundbreaking approach with encouraging outcomes for mCRPC patients. With minimal toxicity and high response rates, SYNC-T presents a significant potential as a viable treatment option. Further clinical trials are eagerly awaited to assess its progress.

SYNC-T utilizes a unique combination of partial tumor lysis and intratumoral immunotherapy. Firstly, freezing is employed to disrupt a portion of the target tumor, facilitating the release of cancer-specific signals and activating the immune system. Subsequently, a fixed-dose multi-target drug, SV-102, is directly administered into the tumor site to further stimulate the immune response and block immune-suppressive mechanisms. This innovative approach aims to empower the immune system to recognize and combat patient-specific cancer throughout the body. The direct injection of SV-102 into the tumor enables the use of significantly smaller doses compared to systemic IV administration, potentially reducing side effects and toxicity.

Dr. George Prendergast, President and CEO of the Lankenau Institute for Medical Research (LIMR), emphasized the unprecedented clinical response observed in mCRPC, particularly noting a complete response in a subject with advanced bone metastases. These remarkable outcomes position SYNC-T as a first-in-class therapy deserving further clinical investigation.

The Phase 1 trial enrolled 15 mCRPC subjects, most of whom had diffuse bone metastases and had previously failed with other therapies. SYNC-T therapy with SV-102 was administered every four weeks for up to 12 cycles, with response evaluations conducted every eight weeks. The therapy demonstrated an ORR of 85%, with five complete responses (CRs) and six partial responses (PRs) among the evaluable subjects. Importantly, the treatment was well tolerated with minimal side effects and no significant safety concerns.

These promising results support the ongoing clinical development of SYNC-T Therapy platform as a potential new treatment option for patients with mCRPC and other solid tumors. The inclusion of the trial in AACR’s press program underscores the interest and significance of these findings within the oncology research community.

Reference: Syncromune® Inc, April 08, 2024.  Syncromune® Inc. Presents Positive Results (85% Overall Response Rate) from SYNC-T™ SV-102 Phase 1 Trial in Prostate Cancer at AACR Annual Meeting 2024. https://www.biospace.com/article/syncromune-inc-presents-positive-results-from-sync-t-sv-102-phase-1-trial-at-aacr-annual-meeting-2024

Related Posts

Blog 21 de mayo de 2024
Blog 20 de mayo de 2024
Blog 06 de mayo de 2024
1 2 3 111